Obesity, Type 2 diabetes
Conditions
Interventions
Sponsors
Shanghai Sixth People's Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. When the Informed Consent (ICD) is signed, it is 18 to 65 years old (including 18 and 65 years old); 2. The body mass index (BMI) of the obese group exceeded 28kg / m2 (including 28kg / m2); the body mass index (BMI) of the control group was less than 18.5kg / m2 to 24kg / m2 (including 18.5kg / m2 and not including 24kg / m2) ; 3. Education level: junior high school and above; 4. Willing and able to comply with the research process specified in the program; 5. Able to understand and sign the research informed consent.
Exclusion criteria
Exclusion criteria: 1. fasting plasma glucose = 6.1mmol / L or 2 hours postprandial plasma glucose or random plasma glucose = 7.8mmol / L or a history of T2DM; 2. History of drug and/or alcohol abuse within 2 years prior to screening visits; 3. Previously received any major gastrointestinal surgery (eg, any gastrointestinal surgery for resection, etc.). Allow previous history of gastrointestinal surgery including: appendectomy, cholecystectomy, liver biopsy, and endoscopic surgery; 4. women of childbearing age, pregnant or lactating during screening, surgery, or planning for pregnancy within one year after surgery; 5. In line with DSM-IV schizophrenia, bipolar disorder, depression and other mental illness diagnosis or medical history; 6. Mental illnesses that may affect clinical research compliance, including dementia, active psychosis, major depression, or attempted suicide; 7. Those with severe physical illness who meet any of the following conditions: (1) inflammatory diseases of the gastrointestinal tract, including severe refractory esophagitis, gastric ulcer, duodenal ulcer, or specific inflammation that has been active for the past 10 years, such as Crohn's disease or ulcerative colitis; (2) severe liver dysfunction or end-stage renal disease; (3) glutamic acid decarboxylase antibody (GAD-AB), protein tyrosine phosphatase antibody (IA2-AB) abnormal; or (4) low immune function, for example caused by long-term oral steroid hormones, cancer chemotherapy drugs, or immunodeficiency diseases; 8 Participate in any other clinical study (except for registration or research studies) within 30 days prior to Visit 1 (screening visit) or during the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| EEG signal acquisition;Questionnaire evaluation; | — |
Countries
China
Contacts
Public ContactHaoyong Yu
Department of Endocrinology and Metabolism, Shanghai Sixth People's Hospital
Outcome results
None listed